By Fineline Cube 
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving trade secret disputes and establishing revenue sharing for six ADC programs. Kelun-Biotech had filed criminal and civil complaints in 2024‑2025; under the settlement, Medilink will share past and future licensing and sales revenues from YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL3), YL221 (EGFR), and YL222 (PD‑L1) ADC assets.
Settlement Overview
| Parties | Dispute History | Resolution |
|---|---|---|
| Kelun-Biotech (Plaintiff) | Filed criminal complaint (2024) and civil lawsuits (2025) | Alleged trade secret infringement and harm to interests |
| Medilink Therapeutics (Defendant) | Counterparty in legal proceedings | Agreed to revenue sharing settlement |
| Legal Status | All disputes resolved | Settlement agreement terminates all active litigation |
Revenue Sharing Terms
| Asset | Target | Revenue Share Scope |
|---|---|---|
| YL201 | B7H3 | Past out‑licensing revenue + future sales |
| YL202 | HER3 | Past out‑licensing revenue + future sales |
| YL211 | cMet | Past out‑licensing revenue + future sales |
| YL212 | DLL3 | Past out‑licensing revenue + future sales |
| YL221 | EGFR | Past out‑licensing revenue + future sales |
| YL222 | PD‑L1 | Past out‑licensing revenue + future sales |
Financial Impact: Proportion of revenues undisclosed; estimated $50‑100 million near‑term based on Medilink’s recent licensing deals.
Strategic Implications
- For Kelun-Biotech: Settlement monetizes previously contested IP without further litigation risk; provides non‑dilutive revenue stream from six ADC programs; validates proprietary ADC platform and targeting strategy.
- For Medilink: Resolves legal overhang; retains operational control while sharing economics; preserves ability to advance pipeline with partners (e.g., recent out‑licensing to global pharma).
- For ADC Market: Demonstrates IP value in targeted oncology platforms; revenue‑sharing model may become template for similar disputes; six targets address $15 billion combined ADC market opportunity.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding revenue estimates, settlement enforceability, and market impact. Actual results may differ due to partner commercial performance, regulatory changes, or legal interpretation.-Fineline Info & Tech